Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort
Male
Pru p 3
Longitudinal Studie
0302 clinical medicine
Risk Factors
Surveys and Questionnaires
Prevalence
Longitudinal Studies
Prospective Studies
Child
Rhinitis
Skin Test
Allergen
longitudinal study
Bet v 1; IgE; Phl p 1; Phl p 5; Pru p 3; allergic rhinitis; asthma; biomarkers; children; comorbidities; longitudinal study; pollen; prediction; Adolescent; Allergens; Asthma; Biomarkers; Child; Disease Progression; Female; Follow-Up Studies; Humans; Immunoglobulin E; Italy; Longitudinal Studies; Male; Prevalence; Prospective Studies; Rhinitis, Allergic; Risk Factors; Skin Tests; Surveys and Questionnaires
3. Good health
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA
Italy
pollen
Disease Progression
biomarker
Female
IgE
allergic rhiniti
Human
comorbiditie
Adolescent
610
Follow-Up Studie
03 medical and health sciences
Allergic
children
Bet v 1
616
Humans
Skin Tests
Risk Factor
Allergic rhinitis; Asthma; Bet v 1; Biomarkers; Children; IgE; Phl p 1; Phl p 5; Pru p 3; comorbidities; longitudinal study; pollen; prediction
allergic rhinitis; asthma; Bet v 1; biomarkers; children; comorbidities; IgE; longitudinal study; Phl p 1; Phl p 5; pollen; prediction; Pru p 3; Adolescent; Allergens; Asthma; Biomarkers; Child; Disease Progression; Female; Follow-Up Studies; Humans; Immunoglobulin E; Italy; Longitudinal Studies; Male; Prevalence; Prospective Studies; Rhinitis, Allergic; Risk Factors; Skin Tests; Surveys and Questionnaires
prediction
asthma
Allergens
Immunoglobulin E
Rhinitis, Allergic
Phl p 5
Asthma
Prospective Studie
Phl p 1
allergic rhinitis; asthma; Bet v 1; biomarkers; children; comorbidities; IgE; longitudinal study; Phl p 1; Phl p 5; pollen; prediction; Pru p 3
Biomarkers
Follow-Up Studies
DOI:
10.1111/pai.13036
Publication Date:
2019-02-08T01:35:13Z
AUTHORS (29)
ABSTRACT
AbstractBackgroundPollen‐related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross‐sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR.MethodsDuring 2015‐2017 (follow‐up), we re‐examined 401 patients from those enrolled in 2009‐2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK‐Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors.ResultsThe average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow‐up. SAR persisted in 93.3% of patients at follow‐up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow‐up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow‐up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow‐up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS.ConclusionsSeasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (40)
CITATIONS (28)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....